Clinical trials
Relapse Leukemia clinical trials
Below are recruiting relapse leukemia clinical trials, each written for real people, not researchers. We’re tracking 237 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04881240RecruitingPhase 1
Donor-made memory T-cell therapy for hard-to-treat leukemia
This Phase 1 study tests an immune-cell therapy made from a matched donor to treat relapsed or refractory CD19-positive leukemia. It may help patients who have limited options, especially those who cannot receive the standard donor-cell or self-made (autologous) CD19 CAR T-cell therapy.
Memphis, TennesseeAges Up to 21 years - NCT05506332RecruitingPhase 1
Venetoclax plus leukemia drugs for AML after treatment failure
This Phase 1 trial studies whether a combination of venetoclax (ABT-199) and “purine analogues” can help adults with AML that has come back or didn’t respond to earlier treatment. It’s designed to test safety and early effectiveness in people who haven’t previously developed resistance to venetoclax.
Edegem, AntwerpAges 18 years+ - NCT06561152RecruitingPhase 1/Phase 2
Tagraxofusp plus low-intensity chemo for CD123+ AML
This trial tests a drug called tagraxofusp combined with a gentle chemotherapy regimen for people whose acute myeloid leukemia (AML) has come back or not responded to an initial venetoclax-based treatment. The study focuses on patients whose leukemia cells have a protein called CD123 on their surface.
Palo Alto, CaliforniaAges 18 years+ - NCT06316856RecruitingPhase 1/Phase 2
Targeted immune cell therapy for resistant T-cell cancers
This trial tests a new immune cell therapy (CAR T-cells) that targets CD5 found on certain T-cell cancers. It may be an option for people whose cancer has not responded to other treatments.
Beijing, Beijing MunicipalityAges 1–70 - NCT07347418RecruitingPhase 1
CD64 CAR T cell therapy for relapsed or refractory AML
This trial tests a type of immunotherapy called CAR T cells that target a protein called CD64 on leukemia cells. It is for adults with AML that has come back or not responded to treatment, including venetoclax.
Aurora, ColoradoAges 18 years+ - NCT07137637RecruitingPhase 1
HPB-092 for relapsed or refractory AML
This trial tests a new drug, HPB-092, in adults with acute myeloid leukemia that has come back or not responded to treatment. The goal is to see if it can help when other treatments have not worked.
TianjinAges 18 years+ - NCT04684147RecruitingPhase 2
CNCT19 cell therapy for relapsed or refractory ALL
This Phase 2 study tests an infusion of modified immune cells (CNCT19) in people with acute lymphoblastic leukemia (ALL) that has come back or did not respond to treatment. It may help by targeting leukemia cells that have a specific marker called CD19.
Beijing, Beijing MunicipalityAges 18–65 - NCT05726110RecruitingPhase 3
Selinexor for relapsed or refractory AML in combination treatments
This Phase 3 trial studies selinexor (a medicine that changes signals inside cancer cells) used together with other leukemia treatment regimens for adults whose acute myeloid leukemia (AML) has come back or did not respond to standard therapy. It may help people reach remission or control the disease better than the current approach.
Taiyuan, ShanxiAges 18–60 - NCT06125652RecruitingPhase 1/Phase 2
Anti-Tim-3/CD123 CAR T-cell therapy for resistant AML
This study tests a special immune cell therapy (CAR T-cells) that targets two proteins on leukemia cells. It is for people whose AML has returned or not responded to standard treatments.
Xuzhou, JiangsuAges 18–70 - NCT05190471RecruitingPhase 1
Study drug for adults with AML that did not respond or returned
This Phase 1 study tests BP1002 in adults with acute myeloid leukemia (AML) that is refractory (not responding) or relapsed (coming back). It’s early-stage, aiming to find a safe dose and see if the treatment can help people with limited options.
La Jolla, CaliforniaAges 18 years+ - NCT06343090Recruiting
Comparing two CAR T cell treatments for children and adults with B-ALL
This trial tests whether giving two types of CAR T cells (CD19 and CD22) one after the other works better than giving just one type (CD19) followed by a stem cell transplant for people whose B-cell acute lymphoblastic leukemia (B-ALL) has come back or not gone away. The goal is to see which approach offers a better chance of long-term remission.
Beijing, Beijing MunicipalityAges 1–70 - NCT07070323RecruitingPhase 1/Phase 2
Nanobody CD5-CAR T cells for T-cell cancers
This trial tests a new treatment using your own or a donor's immune cells to fight certain T-cell cancers that haven't responded to standard therapies. It may help people who have few other options left.
Beijing, Beijing MunicipalityAges 1–70 - NCT06802315RecruitingPhase 2
Radiation therapy before stem cell transplant for high-risk blood cancers
This trial tests a precise type of radiation called intensity modulated total marrow irradiation before a stem cell transplant. It aims to destroy cancer cells while reducing side effects for patients with high-risk leukemia or myelodysplastic syndrome.
Chicago, IllinoisAges 18–65 - NCT05270200RecruitingPhase 1/Phase 2
Azacitidine and chidamide after transplant to prevent AML relapse
This trial tests two medicines given after a bone-marrow transplant to help lower the chance of acute myeloid leukemia (AML) coming back. It is aimed at people with higher-risk AML and checks safety along with whether the medicines can help prevent relapse.
Guanzhou, GuandongAges 18–60 - NCT05241093RecruitingPhase 2
HYML-122 plus cytarabine for FLT3-positive relapsed AML
This trial studies HYML-122 together with cytarabine to treat adults with FLT3-positive acute myeloid leukemia (AML) that has come back or did not respond to prior treatment. It may help shrink the leukemia and improve blood-count recovery when standard treatments haven’t worked.
Suzhou, JiangsuAges 18 years+ - NCT05241106RecruitingPhase 2
HYML-122 for FLT3-mutated AML that came back or did not respond
This Phase 2 trial studies HYML-122 in adults with acute myeloid leukemia (AML) that has either come back or did not respond to prior treatment. It targets tumors with an FLT3 mutation and may offer a new treatment option if your AML is resistant or relapsed.
Suzhou, JiangsuAges 18 years+ - NCT05211570RecruitingPhase 1/Phase 2
Study drug AB8939 for AML after prior treatments
This Phase 1/2 study tests AB8939 in people with acute myeloid leukemia (AML) whose disease has come back or did not respond to earlier treatment. It may help researchers find a safe dose and learn whether the treatment can control the leukemia.
Houston, TexasAges 18 years+ - NCT06287528RecruitingPhase 1
CAR T‑cell therapy with IL‑18 for returning B‑cell leukemia
This trial tests a new type of CAR T‑cell therapy that also makes an immune‑boosting protein called IL‑18. It is for people with B‑cell acute lymphoblastic leukemia that has come back or not gone away after standard treatments.
Basking Ridge, New JerseyAges 17 years+ - NCT03850574RecruitingPhase 1/Phase 2
Tuspetinib for relapsed or hard-to-treat AML
This early-phase study tests tuspetinib in people with AML that has come back or did not respond to treatment. The goal is to learn whether it is safe and tolerable, how the drug behaves in the body, and whether it shows signs of benefit.
Birmingham, AlabamaAges 18 years+ - NCT07105579RecruitingPhase 2
Blinatumomab and donor cells after transplant for high-risk B-ALL
This trial tests whether giving two drugs—blinatumomab (an immunotherapy) and donor lymphocyte infusions (white blood cells from your donor)—can help prevent leukemia from coming back after a stem cell transplant for high-risk B-ALL. It is for people who are in remission with no sign of leukemia cells.
HangzhouAges 14–65 - NCT05105152RecruitingPhase 1
CAR T cell therapy for kids with CD33 AML that came back
This Phase 1 study tests a type of lab-made immune cell therapy (CAR T cells) made from your T cells to treat AML that has relapsed or not responded, as long as the cancer shows a marker called CD33. The goal is to see if the treatment is safe and can help control AML after it returns or resists standard therapy.
Seattle, WashingtonAges Up to 30 years - NCT06418776RecruitingPhase 3
Comparing treatments for AML that returns or doesn't respond
This study compares two different treatments for people whose AML did not go away with initial therapy or came back early. It aims to find which approach works better.
MoscowAges 18 years+ - NCT05705570RecruitingPhase 1
CAR-T for CD19-positive relapsed or resistant blood cancers
This trial tests a type of immune treatment (CAR-T cells) for blood cancers that have come back or did not respond after standard treatments. It is for tumors that have CD19 on their cells, aiming to reduce the cancer and improve remission chances.
São Paulo, São PauloAges 2–70 - NCT06472128Recruiting
New digital app for adults with acute myeloid leukemia
This study tests a digital application to help patients with acute myeloid leukemia (AML) during their hospital stay. It may assist with tracking symptoms, education, or communication with care teams.
Boston, MassachusettsAges 18–120
Hear when a new Relapse Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapse leukemia?
- Yes. Clin2 currently lists 237 recruiting relapse leukemia studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapse leukemia trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapse leukemia trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.